Some pharmaceutical companies are cutting deals with insurers to favor brand-name products over cheaper versions.
The California Democrat attended a fundraising event held by a big-pharma lobbying firm a week after constituents booed her stance on single-payer health care. (Pictured, a protester at a Feinstein event in February.)
Two new articles dive into the ways in which the pharmaceutical industry has gamed the market forces behind U.S. drug prices, and how sweetheart deals between doctors and financing firms are gouging the economically vulnerable.
Uplifting as it was to see insurance executives, pharmaceutical manufacturers, hospital officials and doctors gather at the White House on May 11, pledging cooperation toward health care reform, nothing they said or did was inconsistent with precisely the opposite objective.